Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$195.45 USD

195.45
3,453,379

-1.37 (-0.70%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Johnson & Johnson, NVIDIA, Cisco, AbbVie and Sony

The Zacks Analyst Blog Highlights: Johnson & Johnson, NVIDIA, Cisco, AbbVie and Sony

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed at $104.70 in the latest trading session, marking a +1.21% move from the prior day.

Mark Vickery headshot

Top Analyst Reports for Johnson & Johnson, NVIDIA & Cisco

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), NVIDIA Corporation (NVDA) and Cisco Systems, Inc. (CSCO).

Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix

Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.

AbbVie (ABBV) Outperforms Industry Year to Date: Here's Why

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.

Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day

Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed at $102.80 in the latest trading session, marking a -0.88% move from the prior day.

Benjamin Rains headshot

3 Stocks with Strong Dividends to Buy for Growth in 2021

Investors might want to consider adding stocks to their 2021 portfolios that pay a solid dividend and provide exposure to growth areas...

Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $104.64, marking a +1.77% move from the previous day.

Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal

Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.

Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV

Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.

AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications

AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.

AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion

AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.

Benjamin Rains headshot

3 Large-Cap Dividend Stocks to Buy and Hold Before 2021

Investors might not want to jump into stocks that are banking on a highly successful vaccine rollout. Therefore, we focused on 3 large-cap giants from completely different industries that pay a dividend and look poised to grow no matter what happens...

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates

An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.

AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study

AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.

Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates

Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.

Kinjel Shah headshot

Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates

Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.

The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology

The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology

AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier

AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.

Sheraz Mian headshot

Top Stock Reports for Facebook, Netflix & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Netflix, Inc. (NFLX) and AbbVie Inc. (ABBV).

Tracey Ryniec headshot

3 Top Lessons Learned from Buffett's 2020 Portfolio Moves

During a global pandemic, Berkshire Hathaway has re-tooled its portfolio. Maybe it's time you do the same?

Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie

Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie

AbbVie (ABBV) Up 30% Since Last Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.